Home >> Science >> Scientific Overview


 Scientific Overview
   The Epitope-based
   Scientific Publications
Scientific Overview
Influenza viruses are vulnerable to frequent changes in their haemagglutinin (HA) and neuraminidase (NA) surface proteins (especially type A viruses), resulting in new virus strains unfamiliar to the immune system. Antibodies in the blood and other cells of the immune system, which are responsible for protection against repeated infection with the virus, are less effective if the virus surface protein changes; the greater the change, the less effective is the body’s immune defense following natural immunization (via infection) or vaccination.

BiondVax’s Approach
BiondVax’s approach uses a combination of conserved epitopes derived from the influenza virus as immunogens, forming the vaccine. The "conserved epitopes" are common to most human flu virus strains regardless of their antigenic drift and shifts. These conserved epitopes are used to activate the human immune system in a long-lasting and effective manner against known and future strains of the influenza virus. These conserved epitopes are restricted to the viral structure and are not shared by any human protein, thus they are unlikely to induce an autoimmune phenomenon.

The chosen peptides have three primary distinctive qualities:
  • Immunogenicity: the selected peptides are immunogenic thus induce specific immune responses after exposure to the vaccine. A peptide that is immunogenic is also known as an epitope. These responses are reactivated following natural infection.
  • Conserved epitopes: the epitopes are "conserved" i.e., they are not vulnerable to antigenic changes and remain unchanged despite changes that occur in other peptides forming part of the virus' protein. This quality enables the vaccine to induce an immune response to a wide variety of virus strains, thus the term "a universal multi-season/multi-strain vaccine".
  • Combination of epitopes: The specific selection of conserved epitopes induce production of antibodies (by B-cells = humoral arm) and a variety of T-cells (= cellular arm). The activation of both arms of the immune system is responsible for the enhanced effect of this vaccine.

Key Benefits
  • Multi-strain protection thus multi-season coverage. One vaccination schedule is expected to confer three to five years protection against the flu.
  • Year-round vaccination is possible independent of the flu season and according to patient preferences and health authorities’ multi year vaccination program.
  • Short production cycle: Recombinant technology allows year-round production planning, and marketing optimization.

Go Back  Print  Send Page

BiondVax Pharmaceuticals Ltd.
Science Park, 14 Einstein Street

PO Box 4143

Ness Ziona, 74140, Israel

Follow BiondVax on:


© BiondVax Pharmaceuticals Ltd, 2007 - 2011 All rights reserved  l   Disclaimer
Email:  info@biondvax.com
Phone:  +972 8 930 2529
Fax:  +972 8 930 2531
Add to Favorites           Make Us Your Home Page           Site Map